rocketpharma.com (RCKT) - Company Sales Revenue

Rocket Pharmaceuticals relies on its own cGMP facility for gene vector production to ensure process stability. Business prospects depend on clinical trial outcomes and distribution rights in the EU and US. The company's aggregate sales volume on the GURU.Markets daily chart reflects demand dynamics, where the 0.00 mark serves as a key metric. However, a narrow focus on rare pathologies creates extreme binary risk.

Rocket Corp (RCKT): Company Revenue from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Rocket Pharma (RCKT)

- stock price and consensus target price:

Quote Chart Rocket Pharmaceuticals|RCKT - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Rocket Pharma|RCKT - Enterprise Value

- balance sheet net asset value indicators:

Book Value per Share Rocket Pharmaceuticals|RCKT - Company Book Value|Market Value to Book Value rocketpharma.com|RCKT - Aggregate Company Assets

- debt and solvency information:

- net income and valuation ratios data:

RCKT - Net Income|Future Net Profit Rocket Pharmaceuticals|RCKT - P/E Multiple|Market Cap to Projected Earnings Rocket Pharmaceuticals, Inc.|RCKT - PEG Multiple|Enterprise Value to EBITDA Ratio Rocket Pharma|RCKT - Operating profit EBITDA|Net earnings per share (EPS TTM) Rocket Pharmaceuticals|RCKT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months rocketpharma.com|RCKT - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Rocket Pharmaceuticals

- sales volume and revenue indicators:

RCKT - Company Revenue|Company Future Revenue Rocket Pharmaceuticals|RCKT - P/S Multiple|Forward Price-to-Revenue Multiple Rocket Pharmaceuticals Inc

Summary company analysis:RCKT Rocket Pharmaceuticals

Signature product of Rocket Pharmaceuticals, Inc.

For Rocket Pharmaceuticals (RCKT), a leader in developing gene therapies for rare pathologies, revenue serves as a key marker for the commercialization of innovations. This metric aggregates total cash flow from product sales, reflecting actual market demand for the drugs. The company's current sales volume illustrates the dynamics of inflows on a daily basis. This indicator allows for an assessment of the effectiveness of integrating viral vectors into clinical practice. Stable growth confirms the viability of the business model within the high-tech medicine sector.

Key competitors